Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients with Relapsed Non-Hodgkin's B-Cell Lymphoma
Phase of Trial: Phase I
Latest Information Update: 13 Dec 2017
At a glance
- Drugs MT 3724 (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man
- Sponsors Molecular Templates
- 07 Dec 2017 Planned number of patients changed from 40 to 60.
- 07 Dec 2017 Planned End Date changed from 1 Jun 2018 to 1 Sep 2019.
- 07 Dec 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Sep 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History